How to examine patients using the Abnormal Involuntary Movement Scale
- PMID: 2906320
- DOI: 10.1176/ps.39.11.1172
How to examine patients using the Abnormal Involuntary Movement Scale
Abstract
The Abnormal Involuntary Movement Scale (AIMS) examination has been widely recommended for periodic screening for tardive dyskinesia and follow-up of patients diagnosed with the disorder. However, few guidelines exist about how to use the examination in clinical practice. The authors discuss for whom, when, and how the AIMS examination can be used in a multidisciplinary setting; amplify the original instructions for the examination; and propose conventions to clarify scoring. Noting that the AIMS examination is not specific for tardive dyskinesia, they discuss a clinical approach to the patient who is found to have abnormal movements. The AIMS examination is best conducted within the context of an ongoing treatment program, the authors say, and should be part of the informed consent process necessary with patients treated with neuroleptic drugs.
Similar articles
-
CMHC practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs.Hosp Community Psychiatry. 1994 Apr;45(4):343-6. doi: 10.1176/ps.45.4.343. Hosp Community Psychiatry. 1994. PMID: 7912689
-
Screening for tardive dyskinesia.J Clin Psychiatry. 1986 Feb;47(2):75-7. J Clin Psychiatry. 1986. PMID: 2867994
-
Who should perform the AIMS examination?Hosp Community Psychiatry. 1990 Aug;41(8):912-5. doi: 10.1176/ps.41.8.912. Hosp Community Psychiatry. 1990. PMID: 1976108
-
Neuroleptic-induced respiratory dyskinesia.J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):223-9. doi: 10.1176/jnp.7.2.223. J Neuropsychiatry Clin Neurosci. 1995. PMID: 7626967 Review.
-
Tardive dyskinesia: a review.Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S49-54. doi: 10.1177/070674379504007s04. Can J Psychiatry. 1995. PMID: 8564917 Review.
Cited by
-
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review.Ment Health Clin. 2023 Oct 2;13(5):225-232. doi: 10.9740/mhc.2023.10.225. eCollection 2023 Oct. Ment Health Clin. 2023. PMID: 38131059 Free PMC article.
-
Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients.Schizophrenia (Heidelb). 2023 Jul 25;9(1):44. doi: 10.1038/s41537-023-00369-6. Schizophrenia (Heidelb). 2023. PMID: 37491364 Free PMC article.
-
Medical and Surgical Treatment for Medication-Induced Tremor: Case Report and Systematic Review.Mov Disord Clin Pract. 2022 May 24;9(5):676-687. doi: 10.1002/mdc3.13463. eCollection 2022 Jul. Mov Disord Clin Pract. 2022. PMID: 35844282 Free PMC article. Review.
-
Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.Eur Psychiatry. 2022 Mar 24;65(1):1-35. doi: 10.1192/j.eurpsy.2022.11. Online ahead of print. Eur Psychiatry. 2022. PMID: 35322769 Free PMC article.
-
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency.Mol Ther. 2022 Feb 2;30(2):509-518. doi: 10.1016/j.ymthe.2021.11.005. Epub 2021 Nov 8. Mol Ther. 2022. PMID: 34763085 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources